NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has reported positive results from its Phase 2a trial of NEO100, a novel therapy for recurrent brain cancer. The data, which was highlighted in a recent update from Stonegate Capital Partners, demonstrates that NEO100 met its primary endpoint, showing a six-month progression-free survival (PFS) rate of 48.9% as measured by RANO 2.0 criteria using Kaplan-Meier estimation, compared to a pre-specified benchmark of 20% (p=0.0047). Additionally, the median overall survival (OS) reached 26.09 months, and the treatment was well-tolerated with no major toxicities reported.
The significance of these findings lies in the current standard of care for recurrent brain cancer. Management noted that existing salvage therapies typically offer only 6–9 months of survival, making NEO100's median OS of 26.09 months a considerable improvement. While the PFS endpoint was met, the survival signal is viewed as the more critical read-through, though confirmation in a randomized controlled trial remains the next essential step.
The positive readout positions NEO100 for a potential registrational program, with the company intending to request a Type B meeting with the FDA to discuss trial design, endpoints, and the approval pathway. This regulatory alignment is seen as a key near-term catalyst for the company, as it could expedite the path to market.
Beyond NEO100, NeOnc's second clinical asset, NEO212, has also gained regulatory momentum. The company has received Phase 2 CMC clearance and FDA feedback indicating a potential accelerated approval pathway for NEO212. This broadening of the investment case beyond a single asset adds to the company's long-term optionality, with NEO100 also being explored for meningioma and pediatric brain tumors.
Financially, the company's R&D expenses increased to $2.6 million in the second quarter of 2026, up from $0.7 million in the same period last year, reflecting the expanded development activities. While funding remains a consideration as the pipeline advances, the recent clinical and regulatory progress underscores the potential of NeOnc's platform.
For more details, the full announcement is available at Stonegate Capital Partners.
